GlassScriptPhysician profile
Jorge W Roig
NPI 1235245341
$3,418.88
in general payments reported to CMS, 2019-2025
30 companies · $257 in 2025
The $257 reported for 2025 was more than what 85% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $329 · 2021: $357 · 2022: $372 · 2023: $417 · 2024: $867 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $542.41 | 2019-2025 | Prialt |
| Medtronic, INC. | $489.58 | 2021-2025 | Osteocool Rf Ablation System, Inceptiv, Kyphon Express II Kyphopak Tray |
| Abbott Laboratories | $374.77 | 2023-2024 | Eterna, Octrode, Proclaim |
| Collegium Pharmaceutical, INC. | $234.10 | 2019-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $227.32 | 2019-2022 | |
| Stimwave Technologies Incorporated | $213.15 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.08 | 2019-2024 | Relistor |
| Sentynl Therapeutics, INC. | $141.64 | 2019-2020 | |
| Forte Bio-Pharma LLC | $127.09 | 2024 | Prolate, Nalocet |
| Pacira Pharmaceuticals Incorporated | $124.99 | 2019 | |
| Redhill Biopharma INC. | $69.23 | 2021-2022 | |
| Si-Bone, INC. | $67.74 | 2020-2024 | |
| Daiichi Sankyo INC. | $65.00 | 2019 | |
| Pfizer INC. | $63.54 | 2019-2021 | |
| Mdd US Operations, LLC | $57.89 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $56.56 | 2022 | |
| Mindray Ds USA, INC. | $49.86 | 2024 | A7 Anesthesia System |
| Radius Health, INC. | $35.98 | 2021 | |
| Medtronic USA, INC. | $34.71 | 2019 | |
| Kaleo, INC. | $32.47 | 2019 | |
| Arbor Pharmaceuticals, INC. | $30.13 | 2022 | |
| Boston Scientific Corporation | $26.46 | 2024 | Wavewriter Alpha Prime 16 |
| Averitas Pharma INC. | $25.38 | 2024 | Qutenza |
| Valinor Pharma, LLC | $21.28 | 2023 | Movantik |
| Ultragenyx Pharmaceutical INC. | $20.41 | 2022 | |
| Pacira Therapeutics, INC. | $17.96 | 2019 | |
| Stryker Corporation | $16.83 | 2021 | |
| Depuy Synthes Sales INC. | $15.66 | 2021 | |
| Virtus Pharmaceuticals LLC | $15.16 | 2024 | Levorphanol Tartrate |
| Foundation Fusion Solutions, LLC | $12.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Roig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.